Healthcare Brief:
AbbVie EU Approval, Bristol Hub Launch

AbbVie ($ABBV) received European Commission approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration botulinum neurotoxin serotype E for adults with moderate to severe glabellar lines, following similar approval in Canada. Boey marks the first approved serotype E neurotoxin in Europe, with effects beginning as early as eight hours and lasting approximately two to three weeks. $ABBV shares closed at $256.18, gaining 1.11% in the latest session. Johnson & Johnson ($JNJ) declared a third quarter 2026 cash dividend of $1.34 per share and raised full year sales guidance to a range of $100.8 billion to $101.4 billion after reporting second quarter results. $JNJ also secured FDA approval for its dual energy THERMOCOOL SMARTTOUCH SF device. Moderna ($MRNA) appointed Michael McDonnell to its Board of Directors and Audit Committee, bringing additional financial and life sciences experience to the governance structure, with shares at $59.66 and year-to-date returns of 93.3%.

Bristol Myers Squibb ($BMY) opened a 427,000 square foot R&D hub at the Campus Point Megacampus in San Diego, delivered by Alexandria Real Estate Equities. The facility brings together research teams and laboratory capacity in a single West Coast center. $BMY is deploying new AI infrastructure built on NVIDIA's latest architecture to support drug discovery across oncology, cardiovascular disease, and other core therapeutic areas. The new San Diego site marks an operational milestone and reflects demand from large multinational pharmaceutical tenants for state-of-the-art research facilities.

Amgen ($AMGN) cleared a key regulatory overhang after a court decision blocked Colorado's planned 70% price cap on Enbrel, removing uncertainty for investors. $AMGN shares delivered a 30-day return of 8.48% and year-to-date return of 11.78%, with one-year total shareholder return of 23.41%. Eli Lilly ($LLY) faces a lawsuit from Novo Nordisk over alleged misleading GLP-1 advertising, drawing attention to how core obesity and diabetes franchises are being marketed. $LLY shares gained 2.49% in the latest session and posted a 30-day return of 6.99%, with one-year total shareholder return of 52.46%. ImmuPharma appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon, completing main manufacturing partnerships alongside Swiss group Bachem.

Molina Healthcare has seen its stock edge down in recent days amid concerns about Medicaid cost pressures, according to reporting on the managed care sector. Elevance Health faces investor focus on Medicaid struggles, though analysis suggests the upside story may be present across other parts of its business. UnitedHealth ($UNH) raised guidance in its latest earnings, but analysts on the company's call zeroed in on an underlying margin divergence running through the business. The managed care segment faces ongoing scrutiny over cost pressures in Medicaid programs.

Gilead Sciences ($GILD) plans to present new HIV research data at AIDS 2026, including long-term efficacy and safety results from lenacapavir. $GILD will also share data on a novel HIV treatment regimen developed with Merck ($MRK). $GILD shares closed at $130.28, with a year-to-date return of 7.1% and one-year return of 21.3%. The presentations connect directly to how the market views the company's HIV portfolio. Novo Nordisk has delivered a three-year total shareholder return down 35.8%, placing recent share price movements in the context of a material drawdown for long-term holders.

Moderna ($MRNA) has an earnings report scheduled for July 31, 2026, drawing attention after the stock declined 3.77% recently and posted a seven-day share price return down 11.54% and 30-day share price return down 6.72%. However, year-to-date share price return of 93.32% and one-year total shareholder return of 82.28% show strong momentum over longer periods. Investors will be watching for updates on the company's pipeline and commercial trajectory. The broader healthcare sector faces a calendar of upcoming clinical trial readouts and regulatory decisions in the coming months.